• 2017
  Dabo S., Maillard P., Collados Rodriguez M., Hansen M. D., Mazouz S., Bigot D. J., Tible M., Janvier G., Helynck O., Cassonnet P., Jacob Y., Bellalou J., Gatignol A., Patel R. C., Hugon J., Munier-Lehmann H., Meurs E. F., Inhibition of the inflammatory response to stress by targeting interaction between PKR and its cellular activator PACT, Sci Rep. 2017 Nov 23;7(1):16129.
• 2015
  Gourmaud S, Paquet C, Dumurgier J, Pace C, Bouras C, Gray F, Laplanche JL, Meurs EF, Mouton-Liger F, Hugon J, Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline, J Psychiatry Neurosci 2015 May;40(3):151-61.
• 2014
  Burugu S, Daher A, Meurs EF, Gatignol A, HIV-1 translation and its regulation by cellular factors PKR and PACT, Virus Res. 2014 Nov;193:65-77.
• 2012
  Dabo S, Meurs EF, dsRNA-dependent protein kinase PKR and its role in stress, signaling and HCV infection, Viruses 2012 Nov;4(11):2598-635.
• 2011
  Arnaud N, Dabo S, Akazawa D, Fukasawa M, Shinkai-Ouchi F, Hugon J, Wakita T, Meurs EF, Hepatitis C virus reveals a novel early control in acute immune response, PLoS Pathog. 2011 Oct;7(10):e1002289.
• 2010
  Arnaud N, Dabo S, Maillard P, Budkowska A, Kalliampakou KI, Mavromara P, Garcin D, Hugon J, Gatignol A, Akazawa D, Wakita T, Meurs EF, Hepatitis C virus controls interferon production through PKR activation, PLoS ONE 2010;5(5):e10575.
• 2010
  Boleti H, Smirlis D, Dalagiorgou G, Meurs EF, Christoforidis S, Mavromara P, ER targeting and retention of the HCV NS4B protein relies on the concerted action of multiple structural features including its transmembrane domains, Mol. Membr. Biol. 2010 Jan;27(1):45-62.
• 2009
  Vitour D, Dabo S, Ahmadi Pour M, Vilasco M, Vidalain PO, Jacob Y, Mezel-Lemoine M, Paz S, Arguello M, Lin R, Tangy F, Hiscott J, Meurs EF, Polo-like kinase 1 (PLK1) regulates interferon (IFN) induction by MAVS, J. Biol. Chem. 2009 Aug;284(33):21797-809.
• 2007
  Andréo U, Maillard P, Kalinina O, Walic M, Meurs E, Martinot M, Marcellin P, Budkowska A, Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection, Cell. Microbiol. 2007 Oct;9(10):2445-56.
• 2007
  Le Goffic R, Pothlichet J, Vitour D, Fujita T, Meurs E, Chignard M, Si-Tahar M, Cutting Edge: Influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells, J. Immunol. 2007 Mar;178(6):3368-72.
• 2006
  Vilasco M, Larrea E, Vitour D, Dabo S, Breiman A, Regnault B, Riezu JI, Eid P, Prieto J, Meurs EF, The protein kinase IKKepsilon can inhibit HCV expression independently of IFN and its own expression is downregulated in HCV-infected livers, Hepatology 2006 Dec;44(6):1635-47.
• 2006
  Breiman A, Vitour D, Vilasco M, Ottone C, Molina S, Pichard L, Fournier C, Delgrange D, Charneau P, Duverlie G, Wychowski C, Maurel P, Meurs EF, A hepatitis C virus (HCV) NS3/4A protease-dependent strategy for the identification and purification of HCV-infected cells, J. Gen. Virol. 2006 Dec;87(Pt 12):3587-98.
• 2006
  Bonnet MC, Daurat C, Ottone C, Meurs EF, The N-terminus of PKR is responsible for the activation of the NF-kappaB signaling pathway by interacting with the IKK complex, Cell. Signal. 2006 Nov;18(11):1865-75.
• 2005
  Breiman A, Grandvaux N, Lin R, Ottone C, Akira S, Yoneyama M, Fujita T, Hiscott J, Meurs EF, Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon, J. Virol. 2005 Apr;79(7):3969-78.
• 2004
  Bonte D, François C, Castelain S, Wychowski C, Dubuisson J, Meurs EF, Duverlie G, Positive effect of the hepatitis C virus nonstructural 5A protein on viral multiplication, Arch. Virol. 2004 Jul;149(7):1353-71.
• 2002
  Dorin D, Bonnet MC, Bannwarth S, Gatignol A, Meurs EF, Vaquero C, The TAR RNA-binding protein, TRBP, stimulates the expression of TAR-containing RNAs in vitro and in vivo independently of its ability to inhibit the dsRNA-dependent kinase PKR, J. Biol. Chem. 2003 Feb;278(7):4440-8.
• 2002
  Wecker K, Bonnet MC, Meurs EF, Delepierre M, The role of the phosphorus BI-BII transition in protein-DNA recognition: the NF-kappaB complex, Nucleic Acids Res. 2002 Oct;30(20):4452-9.
• 2002
  Castelain S, Khorsi H, Roussel J, François C, Jaillon O, Capron D, Penin F, Wychowski C, Meurs E, Duverlie G, , Variability of the nonstructural 5A protein of hepatitis C virus type 3a isolates and relation to interferon sensitivity, J. Infect. Dis. 2002 Mar;185(5):573-83.
• 2001
  Daher A, Longuet M, Dorin D, Bois F, Segeral E, Bannwarth S, Battisti PL, Purcell DF, Benarous R, Vaquero C, Meurs EF, Gatignol A, Two dimerization domains in the trans-activation response RNA-binding protein (TRBP) individually reverse the protein kinase R inhibition of HIV-1 long terminal repeat expression, J. Biol. Chem. 2001 Sep;276(36):33899-905.
• 2000
  Péloponèse JM, Grégoire C, Opi S, Esquieu D, Sturgis J, Lebrun E, Meurs E, Collette Y, Olive D, Aubertin AM, Witvrow M, Pannecouque C, De Clercq E, Bailly C, Lebreton J, Loret EP, 1H-13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein, C. R. Acad. Sci. III, Sci. Vie 2000 Oct;323(10):883-94.
• 2000
  Bonnet MC, Weil R, Dam E, Hovanessian AG, Meurs EF, PKR stimulates NF-kappaB irrespective of its kinase function by interacting with the IkappaB kinase complex, Mol. Cell. Biol. 2000 Jul;20(13):4532-42.
• 2000
  François C, Duverlie G, Rebouillat D, Khorsi H, Castelain S, Blum HE, Gatignol A, Wychowski C, Moradpour D, Meurs EF, Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis, J. Virol. 2000 Jun;74(12):5587-96.
• 2000
  Iordanov MS, Paranjape JM, Zhou A, Wong J, Williams BR, Meurs EF, Silverman RH, Magun BE, Activation of p38 mitogen-activated protein kinase and c-Jun NH(2)-terminal kinase by double-stranded RNA and encephalomyocarditis virus: involvement of RNase L, protein kinase R, and alternative pathways, Mol. Cell. Biol. 2000 Jan;20(2):617-27.
• 1999
  Péloponèse JM, Collette Y, Grégoire C, Bailly C, Campèse D, Meurs EF, Olive D, Loret EP, Full peptide synthesis, purification, and characterization of six Tat variants. Differences observed between HIV-1 isolates from Africa and other continents, J. Biol. Chem. 1999 Apr;274(17):11473-8.
• 1996
  Raveh T, Hovanessian AG, Meurs EF, Sonenberg N, Kimchi A, Double-stranded RNA-dependent protein kinase mediates c-Myc suppression induced by type I interferons, J. Biol. Chem. 1996 Oct;271(41):25479-84.
• 1995
  Meurs EF, McMillan N, Williams BR, Hovanessian AG, Southern PJ, Human PKR transfected into murine cells stimulates expression of genes under control of the HIV1 or HTLV-I LTR, Virology 1995 Dec;214(2):653-9.
• 1995
  Barber GN, Jagus R, Meurs EF, Hovanessian AG, Katze MG, Molecular mechanisms responsible for malignant transformation by regulatory and catalytic domain variants of the interferon-induced enzyme RNA-dependent protein kinase, J. Biol. Chem. 1995 Jul;270(29):17423-8.
• 1995
  Jeffrey IW, Kadereit S, Meurs EF, Metzger T, Bachmann M, Schwemmle M, Hovanessian AG, Clemens MJ, Nuclear localization of the interferon-inducible protein kinase PKR in human cells and transfected mouse cells, Exp. Cell Res. 1995 May;218(1):17-27.
• 1994
  Kadereit S, Galabru J, Robert N, Meurs EF, Hovanessian AG, Characterization of an interferon-induced 48-kD protein immunologically related to the double-stranded RNA-activated protein kinase PKR, J. Interferon Res. 1994 Oct;14(5):251-7.
• 1993
  Kadereit S, Gewert DR, Galabru J, Hovanessian AG, Meurs EF, Molecular cloning of two new interferon-induced, highly related nuclear phosphoproteins, J. Biol. Chem. 1993 Nov;268(32):24432-41.
• 1993
  Squire J, Meurs EF, Chong KL, McMillan NA, Hovanessian AG, Williams BR, Localization of the human interferon-induced, ds-RNA activated p68 kinase gene (PRKR) to chromosome 2p21-p22, Genomics 1993 Jun;16(3):768-70.
• 1993
  Meurs EF, Galabru J, Barber GN, Katze MG, Hovanessian AG, Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase, Proc. Natl. Acad. Sci. U.S.A. 1993 Jan;90(1):232-6.
• 1992
  Barber GN, Tomita J, Garfinkel MS, Meurs E, Hovanessian A, Katze MG, Detection of protein kinase homologues and viral RNA-binding domains utilizing polyclonal antiserum prepared against a baculovirus-expressed ds RNA-activated 68,000-Da protein kinase, Virology 1992 Dec;191(2):670-9.
• 1992
  Meurs EF, Watanabe Y, Kadereit S, Barber GN, Katze MG, Chong K, Williams BR, Hovanessian AG, Constitutive expression of human double-stranded RNA-activated p68 kinase in murine cells mediates phosphorylation of eukaryotic initiation factor 2 and partial resistance to encephalomyocarditis virus growth, J. Virol. 1992 Oct;66(10):5805-14.
• 1992
  Chong KL, Feng L, Schappert K, Meurs E, Donahue TF, Friesen JD, Hovanessian AG, Williams BR, Human p68 kinase exhibits growth suppression in yeast and homology to the translational regulator GCN2, EMBO J. 1992 Apr;11(4):1553-62.
• 1991
  Katze MG, Wambach M, Wong ML, Garfinkel M, Meurs E, Chong K, Williams BR, Hovanessian AG, Barber GN, Functional expression and RNA binding analysis of the interferon-induced, double-stranded RNA-activated, 68,000-Mr protein kinase in a cell-free system, Mol. Cell. Biol. 1991 Nov;11(11):5497-505.
• 1991
  Barber GN, Tomita J, Hovanessian AG, Meurs E, Katze MG, Functional expression and characterization of the interferon-induced double-stranded RNA activated P68 protein kinase from Escherichia coli, Biochemistry 1991 Oct;30(42):10356-61.
• 1990
  Meurs E, Chong K, Galabru J, Thomas NS, Kerr IM, Williams BR, Hovanessian AG, Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon, Cell 1990 Jul;62(2):379-90.
• 1988
  Meurs E, Hovanessian AG, Alpha-interferon inhibits the expression of heavy chain mu messenger RNA in Daudi cells, EMBO J. 1988 Jun;7(6):1689-96.
• 1987
  Hovanessian AG, Galabru J, Meurs E, Buffet-Janvresse C, Svab J, Robert N, Rapid decrease in the levels of the double-stranded RNA-dependent protein kinase during virus infections, Virology 1987 Jul;159(1):126-36.
• 1985
  Meurs E, Krause D, Robert N, Silverman RH, Hovanessian AG, The 2-5A system in control and interferon-treated K/BALB cells infected with encephalomyocarditis virus, Prog. Clin. Biol. Res. 1985;202:307-15.
• 1984
  Laurent AG, Gruest J, Svab J, Montagnier L, Meurs E, Purification of the major species of human leucocyte interferon with the help of a monoclonal antibody, Dev. Biol. Stand. 1984;57:305-10.
• 1982
  Meurs E, Rougeot C, Svab J, Laurent AG, Hovanessian AG, Robert N, Gruest J, Montagnier L, Dray F, Use of an anti-human leukocyte interferon monoclonal antibody for the purification and radioimmunoassay of human alpha interferon, Infect. Immun. 1982 Sep;37(3):919-26.
• 1981
  Meurs E, Hovanessian AG, Montagnier L, Interferon-mediated antiviral state in human MRC5 cells in the absence of detectable levels of 2-5A synthetase and protein kinase, J. Interferon Res. 1981 Feb;1(2):219-32.
• 1980
  Hovanessian AG, Meurs E, Aujean O, Vaquero C, Stefanos S, Falcoff E, Antiviral response and induction of specific proteins in cells treated with immune T (type II) interferon analogous to that from viral interferon (type I)-treated cells, Virology 1980 Jul;104(1):195-204.
• 1979
  Meurs E, D'Ari R, Prophage substitution and prophage loss from superinfected Escherichia coli recA(P1) lysogens, J. Virol. 1979 Aug;31(2):277-80.
• 1979
  Hovanessian AG, Wood J, Meurs E, Montagnier L, Increased nuclease activity in cells treated with pppA2’p5’A2’p5′ A, Proc. Natl. Acad. Sci. U.S.A. 1979 Jul;76(7):3261-5.